The clinical effect of ulinastatin combined with diphenoxylate efficacy evaluation patients with severe acute pancreatitis / 中国基层医药

ABSTRACT

Objective To investigate ulinastatin combined with diphenoxylate efficacy patients with severe acute pancreatitis.Methods 90 cases with severe acute pancreatitis patients hospital as the object of study,were randomly divided into experimental group and control group,ulinastatin replication treatment control group,the experimental group were treated with ulinastatin joint diphenoxylate adjuvant treatment,and before and after the medical treatment of TNF-α,IL-6,IL-18 the detection,and the treatment efficacy of the patient's evaluation.Results The patients abdominal pain time,signs alleviate time,the white blood cell count recovery time to resume normal serum amylase time,the urine amylase recovery time,average length of stay (4.3 ± 1.4)d vs (6.4 ± 2.3)d,(4.1 ± 1.5)d vs (6.5 ±1.4)d,(7.3 ±3.5)d vs (10.3 ±2.3)d,(4.5 ±l.5)d vs (7.9 ±2.3)d,(5.4±l.2)d vs (8.2 ±2.3)d,(22.3 ±3.7)d vs (31.5 ±3.4)d(t =5.2319,7.846,5,4.8052,8.3061,7.2403,12.2818,all P ＜0.05),the two groups of patients receiving treatment,3d,7d,and 14d of TNF-α,IL-6,IL-18,the levels of endotoxin has statistical difference (P ＜ 0.05) (t =6.3843,8.9328,5.938,4.9381,all P ＜ 0.05),the experimental group patients with an effective rate of 97.78％,88.89％ was significantly better than the control group(x2 =12.932,P ＜ 0.05).Concltusion Ulinastatin combined with diphenoxylate has good clinical efficacy in acute severe pancreatitis,which is worthy of promotion in the clinical.